Evidence map›Paper›PMID 33167690›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2021

Etiological classification and treatment strategies for secondary bile duct dilatation.

Yunfu Lv, Ning Liu, Hongfei Wu, Zhuori Li

Open access · greenAbstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yunfu LvDepartment of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou 570311, China.ORCID 0000-0003-0451-399X
Ning LiuDepartment of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou 570311, China.
Hongfei WuDepartment of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou 570311, China.
Zhuori LiDepartment of General Surgery, Hainan General Hospital (Hainan Medical College Affiliated People's Hospital), Haikou 570311, China.
Hainan General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary intra- and extrahepatic bile duct dilatation is a very common condition that can be caused by several diseases. However, it has been rarely discussed in the specialized literature. Moreover, no distinct etiology can be determined in some cases, which hampers the diagnosis and treatment. Here, we discuss the etiological classification and treatment strategies of secondary intra- and extrahepatic bile duct dilatation based on an extensive literature review, as well as our experimental research and clinical experience. The etiology of secondary intra- and extrahepatic bile duct dilatation can be classified in different ways. From a clinicopathological perspective, it can be classified into obstruction-, lesion-, and compression-induced dilatation. Treatment varies depending on the cause. For example, endoscopic dilation or stenting is used for biliary strictures, laparoscopic choledochectomy for stone removal, and resection for cholangiocarcinoma.

Indexed as

Bile Ducts, ExtrahepaticBile Ducts, IntrahepaticBilirubinCholestasisDilatation, PathologicHumansJaundiceBilirubinBile duct dilatationdiagnosisetiological classificationintra- and extrahepaticsecondarytreatment

Identifiers

PMID33167690
PMCPMC7876649
OpenAlexW3103591674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.